TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15623811
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol therapy (0.05, 0.10, 0.15, and 0.20 mg/d for 4 consecutive days)
Study: 14504183
Drug: Low-dose AdVEGF121
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose AdVEGF121 (4x10^9 PU)
Study: 14504183
Drug: High-dose AdVEGF121
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose AdVEGF121 (4x10^10 PU)
Study: 14504183
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Low-dose, High-dose, Placebo)
Study: 2499174
Drug: Lactase tablet
Normalized name: Lactase
DrugBank: Tilactase (DB13761)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactase tablet (LT)
Study: 336322
Drug: MK-231 (Sulindac),
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-231 (Sulindac), 200-400 mg daily
Study: 29307157
Drug: Vestibular rehabilitation
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular rehabilitation therapy program (exercise intervention) for 8 weeks, including compensatory training, enhancement of visual and somatosensory function, and balance training.
Study: 16461847
Drug: HT-treated (ramipril,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HT-treated (ramipril, 5 to 10 mg/d during 3 months; n=12)
Study: 15268921
Drug: levodopa infusion
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: levodopa infusion
Study: 24967366
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II - parents provided with detailed information about anesthesia administration, drugs used, side effects, and complications.
Study: 20458201
Drug: Integrated motivational
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated motivational interviewing and cognitive behavior therapy
Study: 16186374
Drug: Ruboxistaurin (RBX)
Normalized name: ethanol
DrugBank: Ruboxistaurin (DB11829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruboxistaurin (RBX) 4, 16, or 32 mg/d
Study: 1665400
Drug: Hep‐B Vax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hep‐B Vax vaccine administered at 0, 1, and 6 months after birth (5 or 2.5 micrograms in pilot study, 5 micrograms in main study)
Study: 1665400
Drug: Hep‐B Vax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hep‐B Vax vaccine
Study: 27025835
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir (DCV) 60 mg + Sofosbuvir (SOF) 400 mg for 12 weeks
Study: 22089462
Drug: Non-adjuvanted influenza
Normalized name: Influenza, adjuvanted, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted influenza A H1N1/2009 vaccine
Study: 20538134
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg) plus Simvastatin (40 mg)
Study: 17933700
Drug: Indinavir 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 600 mg BID + Ritonavir 100 mg BID
Study: 17933700
Drug: Indinavir 400
Normalized name: indinavir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 400 mg BID + Ritonavir 100 mg BID
Study: 15686782
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment with anti‐anginal drugs (not specified which drugs or dosages)
Study: 15686782
Drug: Invasive treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive treatments (not specified)
Study: 9867093
Drug: Fructose-sorbitol (F-S)
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose-sorbitol (F-S) mixture (25 g fructose and 5 g sorbitol)
Study: 1648488
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg molsidomine
Study: 2633458
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg isosorbide dinitrate retard
Study: 22674141
Drug: Eltrombopag 12.5
Normalized name: eltrombopag 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 12.5 mg once daily for 2 weeks
Study: 22674141
Drug: Eltrombopag 25
Normalized name: eltrombopag 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 25 mg once daily for 2 weeks
Study: 22674141
Drug: Eltrombopag 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 37.5 mg once daily for 2 weeks
Study: 20953062
Drug: Atorvastatin (80mg/day)
Normalized name: atorvastatin 80 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (80mg/day) for 3 weeks
Study: 17403003
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (20 mg) every 5 min
Study: 12070543
Drug: Metformin (850mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850mg twice daily) plus Clomiphene citrate (50mg, increasing to 200mg)
Study: 7670451
Drug: Lactate supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate supplementation (10 g of lactate as calcium, sodium, and potassium salts, twice a day for 3 weeks)
Study: 7670451
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, twice a day for 3 weeks)
Study: 2073113
Drug: Aerosolized rimantadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized rimantadine at 20 micrograms/liter of air for 12 hours daily for 3 days
Study: 2073113
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of rimantadine at 200 mg
Study: 28435222
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg dexmedetomidine (BD group)
Study: 28435222
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL 0.9% normal saline (BN group)
Study: 23939663
Drug: Adapted simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapted simvastatin doses (ranging from 25 to 80 mg)
Study: 23939663
Drug: Standard simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard simvastatin dose (40 mg)
Study: 23939663
Drug: Low adapted
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low adapted simvastatin dose (12 mg) during CYP3A inhibition with ritonavir
Study: 20933491
Drug: DEC plus
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC plus albendazole (DEC/ALB) combination
Study: 8690148
Drug: Hyperinsulinemic hypoglycemia
Normalized name: Drugs for treatment of hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic hypoglycemia (2.6 +/- 0.1 mmol/l, 47 +/- 1 mg/dl)
Study: 8690148
Drug: Hyperinsulinemic euglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic euglycemia (4.8 +/- 0.1 mmol/l, 86 +/- 5 mg/dl)
Study: 8690148
Drug: Stepped hypoglycemic
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepped hypoglycemic clamps (4.7, 4.2, 3.6, 3.0, 2.8, 2.5, and 2.2 mmol/l)
Study: 20831134
Drug: 5000 ppm
Normalized name: Sodium Fluoride 5000 PPM
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5000 ppm sodium fluoride (F‐gel)
Study: 17506855
Drug: Cetirizine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 50 mg (healthy volunteers)
Study: 11894723
Drug: Monophasic combination
Normalized name: Monobasic Potassium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic combination of EE and GST
Study: 11894723
Drug: Low-dose OCs
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose OCs containing newer gonane progestogens
Study: 7859140
Drug: Thymopentin, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin, 50 mg subcutaneously 3 times per week
Study: 1777589
Drug: Long-term antibiotic
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term antibiotic prophylaxis with trimethoprim-sulfamethoxasole
Study: 6352004
Drug: Cisplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (80 mg/m2) every 3 weeks
Study: 6352004
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus weekly methotrexate (250 mg/m2) with leucovorin
Study: 31851158
Drug: Trimodal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimodal therapy (TMT) consisting of maximal transurethral resection of the bladder tumor followed by concurrent radiosensitizing chemotherapy and radiotherapy
Study: 31851158
Drug: Bladder-sparing therapies
Normalized name: Sus scrofa urinary bladder preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder-sparing therapies (including partial cystectomy, radiation monotherapy, and radical transurethral resection)
Study: 26907659
Drug: Twice-daily low-molecular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily low-molecular weight heparin
Study: 26907659
Drug: Platelet transfusion
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet transfusion to maintain platelet count >50×10/L
Study: 25025601
Drug: Iyengar yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iyengar yoga (IY) program, 6-week duration, twice per week
Study: 22008735
Drug: Escitalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (20 mg) + Gaboxadol (10 mg)
Study: 22008735
Drug: Escitalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (20 mg) + Gaboxadol (5 mg)
Study: 17157479
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 4 mg dexamethasone (Dexason) into the internal pterygoid muscle
Study: 17157479
Drug: LPL irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LPL irradiation supplemented by systemic dexamethasone (4 mg i.m. in deltoid region, followed by 4 mg intraorally 6h postoperatively)
Study: 11053821
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml aprotinin (Trasylol, Bayer AG)
Study: 11053821
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml physiological saline solution
Study: 9363289
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg per day)
Study: 6397218
Drug: Nicardipine 20
Normalized name: nicardipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 20 mg, three times daily
Study: 6397218
Drug: Nicardipine slow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine slow release 30 mg, twice daily
Study: 24396060
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (2 μg kg(‐1) min(‐1))
Study: 19129422
Drug: AZD7009 30-minute
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7009 30-minute 3.25 mg/min
Study: 19129422
Drug: AZD7009 15-minute
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7009 15-minute 3.25 mg/min
Study: 19129422
Drug: AZD7009 15-minute
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7009 15-minute 4.4 mg/min
Study: 19129422
Drug: AZD7009 30-minute
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7009 30-minute 3.25 mg/min (AF episodes <=30 days)
Study: 19129422
Drug: AZD7009 best-dose
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7009 best-dose group
Study: 15734231
Drug: Active 2mg
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active 2mg nicotine lozenge
Study: 12190711
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention program including collaborative treatment plan, monthly telephone monitoring by a nurse care manager, feedback of monitoring results, algorithm-based medication recommendations, outreach and care coordination, structured psychoeducational group program (Life Goals Program).
Study: 7814823
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg oral dose)
Study: 7814823
Drug: Flumazenil (1
Normalized name: Flumazenil (18-F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (1 mg i.v. administered 5 days before baseline)
Study: 2815976
Drug: Purified chick
Normalized name: rabies vaccine, purified chick embryo cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified chick embryo cell (PCEC) rabies vaccine
Study: 2815976
Drug: Human diploid
Normalized name: rabies vaccine, human diploid cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human diploid cell rabies vaccine (HDCV)
Study: 1090337
Drug: Salbutamol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (200 mu g)
Study: 1090337
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (40 mu g)
Study: 1090337
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of salbutamol and ipratropium bromide
Study: 27189595
Drug: FENO-based asthma
Approvals — FDA: no, EMA: no, PMDA: no
Description: FENO-based asthma management (adjusted inhaled corticosteroid dose based on FENO levels)
Study: 27189595
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (one clinical assessment of asthma, self-management education, treatment changes by general practitioner)
Study: 21320109
Drug: Carisbamate 800
Normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carisbamate 800 mg/day
Study: 23692321
Drug: Carisbamate 1200
Normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carisbamate 1200 mg/day
Study: 21968546
Drug: Flow rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flow rate adjusted to heart rate (Group 1: dosage/16)
Study: 17475962
Drug: (18)F-FDG PET
Normalized name: 18-F FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (18)F-FDG PET studies at 1 and 3 weeks after chemotherapy initiation
Study: 12548530
Drug: Prednisone (low-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (low-dose, alternate-day)
Study: 10588224
Drug: High-dose enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose enalapril (40 mg daily)
Study: 10588224
Drug: Low-dose enalapril
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose enalapril (5 mg daily)
Study: 8942297
Drug: Tripotassium dicitrato
Normalized name: Tripotassium dicitratobismuthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripotassium dicitrato bismuthate (240 mg b.i.d.), metronidazole (250 mg t.i.d.), and amoxicillin (500 mg t.i.d.) for 14 days (Group 1)
Study: 8942297
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg b.i.d.) and amoxicillin (1000 mg b.i.d.) for 14 days (Group 2)
Study: 8942297
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg b.i.d.), metronidazole (250 mg t.i.d.), and amoxicillin (500 mg t.i.d.) for 14 days (Group 3)
Study: 8942297
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg q.d.) and amoxicillin (500 mg t.i.d.) for 14 days followed by tripotassium dicitrato bismuthate (240 mg b.i.d.) and nizatidine (150 mg q.d.) for 14 days (Group 4)
Study: 7068113
Drug: chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: chenodeoxycholic acid (CDCA) 375 or 750 mg g.d. for 2 years
Study: 29238184
Drug: Baseline pulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline pulmonary maintenance medication
Study: 27084659
Drug: Proton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton therapy (arm A)
Study: 27084659
Drug: Carbon ion
Normalized name: CARBON ION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon ion therapy (arm B)
Study: 27084659
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (Proton and Carbon ion)
Study: 25149894
Drug: Baru almonds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baru almonds supplementation (20 g/day)
Study: 25149894
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 corn starch capsule/day)
Study: 22573845
Drug: AZT/sdNVP (zidovudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT/sdNVP (zidovudine until delivery with single-dose nevirapine without postpartum prophylaxis)
Study: 19509551
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus vitamin B6 PC6 points injection
Study: 17484670
Drug: Short-term psychodynamic
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term psychodynamic psychotherapy based on supportive-expressive therapy, tailored for social phobia.
Study: 16531939
Drug: Patient-delivered partner
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-delivered partner treatment (PDPT)
Study: 9164180
Drug: Vinblastine, methotrexate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine, methotrexate, and bleomycin (VBM) chemotherapy and regional radiotherapy
Study: 8428718
Drug: Propranolol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.15 mg/kg intravenously)
Study: 27537387
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral medroxyprogesterone acetate (MPA) for 10 days per cycle
Study: 27537387
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral MPA daily for 6 months
Study: 21945889
Drug: HEARTY exercise
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEARTY exercise intervention (a combination of healthy eating, aerobic, and resistance exercise)
Study: 17895895
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum supplementation (11 g per day)
Study: 11396814
Drug: Cisapride (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (0.2 mg/kg dose three times daily)
Study: 9757196
Drug: Epirubicin (30-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (30-40 mg)
Study: 9757196
Drug: Mitoxantrone (6-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (6-8 mg)
Study: 3061042
Drug: 4 times
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 times 10 Gy afterloading therapy combined with 45 Gy percutaneous telecobalt therapy
Study: 3061042
Drug: 5 times
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 times 8 Gy afterloading therapy combined with 45 Gy percutaneous telecobalt therapy
Study: 3061042
Drug: 8 times
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 times 5 Gy afterloading therapy combined with 45 Gy percutaneous telecobalt therapy
Study: 8470417
Drug: Nitroglycerin (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (1.2 mg sublingually)
Study: 8470417
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg capsule, chewed and swallowed)
Study: 151547
Drug: Salbutamol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (200 microgram four times daily)
Study: 151547
Drug: Prednisolone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (10 mg three times daily) in addition to both drugs
Study: 30450642
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg 4MP (fomepizole)
Study: 24314223
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with vinorelbine plus cisplatin (NP)
Study: 24314223
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with docetaxel plus cisplatin (TP)
Study: 19768640
Drug: Budesonide/formoterol (100/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (100/6 microg) once daily plus additional doses as needed (SMART)
Study: 19768640
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated according to guidelines (medium daily doses of ICS plus SABA if needed)
Study: 11718986
Drug: Tumescent technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumescent technique with subdermal injections of epinephrine, thrombin spray, and warm saline soaked laparotomy pads.
Study: 11718986
Drug: Thrombin spray
Normalized name: thrombin Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin spray and warm saline soaked laparotomy pads (control group).
Study: 8124407
Drug: Ephedrine/Caffeine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine/Caffeine combination (20 mg/200 mg) three times a day
Study: 8124407
Drug: Ephedrine alone
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine alone (20 mg) three times a day
Study: 8124407
Drug: Caffeine alone
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine alone (200 mg) three times a day
Study: 3306439
Drug: Oxaprotiline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaprotiline (150 mg daily for 28 days)
Study: 3306439
Drug: Clomipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (150 mg daily for 28 days)
Study: 28165812
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Bupivacaine and Lipid emulsion (Bup1000LE)